/AI%20(artificial%20intelligence)/Businessman%20touching%20the%20brain%20working%20of%20Artificial%20Intelligence%20(AI)%20Automation%20by%20Suttiphong%20Chandaeng%20via%20Shutterstock.jpg)
Artificial intelligence (AI) companies are well-positioned to disrupt the biotechnology industry. Typically, biotech companies need to invest a huge amount of time, capital, and resources to introduce a drug. Most pre-revenue biotech companies have finite access to capital, which incentivizes players to advance drug discovery programs that have the maximum potential to succeed, given the rigorous drug development process.
AI capabilities should help biotech companies better manage these challenges by reducing research, development, and manufacturing costs. This should help biotech players to advance multiple programs at a similar cost.
